Mirvetuximab soravtansine (IMGN853)
Drug timelines are a Plus or Pro feature.
2 regulatory and trial events tracked for Mirvetuximab soravtansine (IMGN853), covering 2025-04-06 to 2025-05-15. Get the full timeline:
Most recent: Clinical Trial Update: A Phase 2 Study of Mirvetuximab Soravtansine (IMGN853) and Pembrolizumab in Endometrial Cancer (EC) [Phase 2]